Literature DB >> 21983927

Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.

Valerio Nobili1, Arun J Sanyal.   

Abstract

Nonalcoholic fatty liver disease encompasses a spectrum of disease from asymptomatic steatosis, with or without elevated aminotransferases, to cirrhosis with relative complications and hepatocellular carcinoma. Owing to the increasing prevalence of nonalcoholic fatty liver disease and the potential for nonalcoholic steatohepatitis to progress to cirrhosis and liver-related mortality, more research has been focused on therapy of this important liver disease over the last two decades. To date, weight loss and physical activity represent the cornerstone of treatment, with interventions being limited to subjects at risk of disease progression, but the type of treatment remains a matter of debate. A few medications have shown promising results in preliminary pilot studies, but few agents have been tested rigorously. Today, multiple therapeutic approaches are considered the way to go in treating nonalcoholic steatohepatitis patients. In this paper we review the status of current and emerging therapeutic strategies for children and adult patients with nonalcoholic steatohepatitis.

Entities:  

Mesh:

Year:  2011        PMID: 21983927     DOI: 10.1007/s00535-011-0467-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  70 in total

1.  Gut-liver axis: a new point of attack to treat chronic liver damage?

Authors:  Carmela Loguercio; Teresa De Simone; Alessandro Federico; Fulvia Terracciano; Concetta Tuccillo; Mauro Di Chicco; Maria Cartenì
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

2.  Statins and hepatic steatosis: perspectives from the Dallas Heart Study.

Authors:  Jeffrey D Browning
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

3.  Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.

Authors:  Valerio Nobili; Giorgio Bedogni; Anna Alisi; Andrea Pietrobattista; Patrizia Risé; Claudio Galli; Carlo Agostoni
Journal:  Arch Dis Child       Date:  2011-01-12       Impact factor: 3.791

4.  Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase.

Authors:  Li-Li Shen; Hong Liu; Jiahe Peng; Lin Gan; Li Lu; Qian Zhang; Liangpeng Li; Fengtian He; Yu Jiang
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

5.  Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis.

Authors:  Deniz G Duman; Filiz Ozdemir; Esra Birben; Ozlem Keskin; Emel Ekşioğlu-Demiralp; Cigdem Celikel; Omer Kalayci; Cem Kalayci
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

6.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

Review 7.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

8.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.

Authors:  Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2009-01-25       Impact factor: 22.682

9.  Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease.

Authors:  L Spadaro; O Magliocco; D Spampinato; S Piro; C Oliveri; C Alagona; G Papa; A M Rabuazzo; F Purrello
Journal:  Dig Liver Dis       Date:  2007-12-04       Impact factor: 4.088

10.  Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

Authors:  Jun Shirakawa; Hideki Fujii; Kei Ohnuma; Koichiro Sato; Yuzuru Ito; Mitsuyo Kaji; Eri Sakamoto; Megumi Koganei; Hajime Sasaki; Yoji Nagashima; Kikuko Amo; Kazutaka Aoki; Chikao Morimoto; Eiji Takeda; Yasuo Terauchi
Journal:  Diabetes       Date:  2011-02-17       Impact factor: 9.461

View more
  3 in total

Review 1.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

2.  Insight Into the Adolescent Patient Experience With Nonalcoholic Fatty Liver Disease.

Authors:  Sanita L Ley; Katherine M Kidwell; Tori R Van Dyk; Sarah Orkin; Cathleen Odar Stough; Taylor Howarth; Amy R Goetz; Stavra A Xanthakos; Kristin Bramlage; Marialena Mouzaki; Ana Catalina Arce-Clachar; Meg H Zeller
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-04-20       Impact factor: 3.288

3.  Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China.

Authors:  Wei-Hui Sun; Ming-Quan Song; Chang-Qing Jiang; Yong-Ning Xin; Jian-Lin Ma; Ying-Xun Liu; Lei Ma; Zhong-Hua Lin; Chang-Yan Li; Ling Liu; Mei Zhang; Lei-Lei Chu; Xiang-Jun Jiang; Qiang Wan; Lin Zhou; Rong Ren; Ling-Fang Meng
Journal:  World J Hepatol       Date:  2012-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.